Stents

This channel includes news and new technology innovations for stents, also called vascular scaffolds. Stents are used to help prop open a vessel treated by balloon angioplasty because of the barotrauma caused by the extreme stretching of vessel walls. The stent enables to vessel to heal in an open position with collapsing. Drug eluting stents (DES) are coated in anti-proliferative drugs to precent scar tissue growth which can cause restenosis and occlude the vessel. DES require antiplatelet therapy because the drug carrier polymer on DES can cause thrombus inside the stent, even years after treatment, which is why bare metal stents are still used in some patients. This page includes news on coronary stents, carotid stents, peripheral stents, bioresorbable stents, and renal stents. 

The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.
Feature | Peripheral Artery Disease (PAD) | Dave Fornell, Editor

The anti-proliferative drug paclitaxel has been used as a coating on coronary stents to prevent restenosis since 2003 ...

Home January 25, 2019
Home
News | Stents

The rise cardiovascular disease has been instrumental in fueling the coronary stent market share in the past few years ...

Home January 22, 2019
Home
News | Peripheral Artery Disease (PAD)

January 17, 2019 — The U.S. Food and Drug Administration (FDA) issued a letter Jan. 17, 2019, to healthcare providers ...

Home January 17, 2019
Home
Blog | Cath Lab

There is a hype cycle surrounding new technologies in all industries, but medicine is unique because of its focus on ...

Home October 16, 2018
Home
Bioresorbable stents (BRS) in development presented by Gregg Stone, M.D., during TCT 2017. Several of the players listed on the slider put their BRS development programs on hold after the negative data from the ABSORB III Trial, but a handful of smaller companies are still pushing the technology forward. #TCT #TCT2018
Feature | Stents Bioresorbable | Dave Fornell, Editor

Bioresorbable stent (BRS) technology is not dead, but the unbridled enthusiasm seen two years ago for the technology has ...

Home October 12, 2018
Home
News | Stents Bioresorbable

October 12, 2018 – Reva Medical presented four key data sets demonstrating the capabilities of the company’s Fantom bior ...

Home October 12, 2018
Home
Videos

Professor Ian Meredith, MBBS, Ph.D., global chief medical officer and executive vice president, Boston Scientific ...

Home October 11, 2018
Home
Videos

A discussion with Professor Ian Meredith, MBBS, Ph.D., global chief medical officer and executive vice president, Boston ...

Home October 11, 2018
Home
Technology | Stents Peripheral

October 5, 2018 — Veryan Medical Ltd has received Premarket Approval (PMA) for the BioMimics 3D Vascular Stent System ...

Home October 05, 2018
Home
News | Stents

October 4, 2018 – Investigators unveiled clinical data from the independent BIONYX and SORT OUT IX all-comers trials ...

Home October 04, 2018
Home
Videos | TCT

DAIC Editor Dave Fornell takes a tour of some of the most innovative new cardiovascular technology he found on the expo ...

Home October 03, 2018
Home
News | Intra-Vascular Ultrasound (IVUS)

October 2, 2018 — Intravascular ultrasound (IVUS) guidance improved clinical outcomes over angiography guidance during d ...

Home October 02, 2018
Home
News | Stents Drug Eluting

October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer ...

Home October 01, 2018
Home
Technology | Stents Drug Eluting

October 1, 2018 — Boston Scientific announced that the U.S. Food and Drug Administration (FDA) has approved its ...

Home October 01, 2018
Home
News | Stents Bioresorbable

October 1, 2018 — New results from the RENASCENT studies presented at the Transcatheter Cardiovascular Therapeutics (TCT ...

Home October 01, 2018
Home
Subscribe Now